This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Successful Treatment With Bromocriptine

Peter S. Mueller, MD; John W. Vester, MD; Joseph Fermaglich, MD

JAMA. 1983;249(3):386-388.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE NEUROLEPTIC malignant syndrome (NMS) is characterized by severe extrapyramidal dysfunction, hyperthermia, and autonomic disturbances following neuroleptic usage.^1,2 This relatively uncommon, potentially lethal syndrome carries a mortality of 20%, yet it is largely unrecognized by physicians and most workers engaged in the neurosciences. Anticholinergic or benzodiazepine treatment, commonly used for neuroleptic neurological side effects, is usually of limited success in the treatment of NMS; a long hospital course with considerable physical disability often is a result in those patients who survive.³ We present two patients with NMS: the first treated in the usual fashion in our medical intensive care unit (ICU), the second on our psychiatric ward, with the rapidly successful and first reported usage of bromocriptine mesylate.

Report of Cases

CASE 1.—

A 28-year-old married woman had been well until Feb 2, 1977, when an acute schizophrenic psychosis with paranoia and catatonia rapidly developed. During her first . . . [Full Text PDF of this Article]

Author Affiliations
From Princeton Medical Center, Princeton, NJ (Drs Mueller and Vester), and the Department of Neurology, Georgetown Medical School, Washington, DC (Dr Fermaglich).

Footnotes
Reprint requests to 905 Herrontown Rd, Princeton, NJ 08540 (Dr Mueller).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?